Minimal time to successful intercourse after sildenafil citrate: Results of a randomized, double-blind, placebo-controlled trial

被引:62
作者
Padma-Nathan, H
Stecher, VJ
Sweeney, M
Orazem, J
Tseng, LJ
deRiesthal, H
机构
[1] Male Clin, Beverly Hills, CA 90212 USA
[2] Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA USA
[3] Pfizer Inc, New York, NY USA
关键词
D O I
10.1016/S0090-4295(03)00567-3
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To determine the minimal time to successful intercourse after taking sildenafil citrate for erectile dysfunction (ED). Methods. Male patients with ED (mean age 60 years; mean ED duration 7.0 years) who were successfully treated with sildenafil (100 mg) for 2 months or longer were randomized to sildenafil (n = 115) or placebo (n = 113) for 4 weeks of double-blind treatment. Using a stopwatch, patients recorded the time needed to obtain an erection hard enough for sexual intercourse after taking the study drug at least 2 hours after eating. Results. Within 14 and 20 minutes of sildenafil dosing, 35% and 51% of sildenafil-treated patients, respectively, versus 22% and 30% of placebo-treated patients, respectively, had an erection that led to successful intercourse (P < 0.05 for both). The median time to erection leading to successful intercourse after sildenafil dosing was 36 minutes compared with 141 minutes for placebo. Conclusions. In this study, slightly more than one half of a population of prior sildenafil responders achieved an erection that led to successful sexual intercourse within 20 minutes of sildenafil administration, suggesting that the onset of action of sildenafil can be less than 30 minutes in men with ED.
引用
收藏
页码:400 / 403
页数:4
相关论文
共 13 条
  • [1] Sildenafil, a novel effective oral therapy for male erectile dysfunction
    Boolell, M
    GepiAttee, S
    Gingell, JC
    Allen, MJ
    [J]. BRITISH JOURNAL OF UROLOGY, 1996, 78 (02): : 257 - 261
  • [2] Onset and duration of action of sildenafil citrate for the treatment of erectile dysfunction
    Eardley, I
    Ellis, P
    Boolell, M
    Wulff, M
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 : 61S - 65S
  • [3] Oral sildenafil in the treatment of erectile dysfunction
    Goldstein, I
    Lue, TF
    Padma-Nathan, H
    Rosen, RC
    Steers, WD
    Wicker, PA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) : 1397 - 1404
  • [4] Kim S, 2002, FORMULARY, V37, P289
  • [5] Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients:: a RigiScan and pharmacokinetic study
    Klotz, T
    Sachse, R
    Heidrich, A
    Jockenhövel, F
    Rohde, G
    Wensing, G
    Horstmann, R
    Engelmann, R
    [J]. WORLD JOURNAL OF UROLOGY, 2001, 19 (01) : 32 - 39
  • [6] The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil citrate in healthy volunteers
    Muirhead, GJ
    Faulkner, S
    Harness, JA
    Taubel, J
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 : 37S - 43S
  • [7] The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate
    Muirhead, GJ
    Wilner, K
    Colburn, W
    Haug-Pihale, G
    Rouviex, B
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 : 21S - 30S
  • [8] NICHOLS DJ, 2002, BR J CLIN PHARM S1, V53, P5
  • [9] Padma-Nathan Harin, 2001, Journal of Urology, V165, P224
  • [10] PADMANATHAN H, 2003, 28 ANN M AM SOC ANDR